Navigation Links
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
Date:9/30/2009

TSX Venture: QPT

EDMONTON, Sept. 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. (TSX:PLB) ("Paladin").

The pipeline of product candidates consists of five monoclonal antibodies targeting certain tumor antigens that are presented in a variety of cancers. The first and most advanced of these product candidates is Oregovomab, an anti-CA125 antibody for the treatment of ovarian cancer patients that Quest will evaluate in combination with front-line chemotherapy.

Quest also acquired anti-MUC1, anti-TAG72, anti-PSA and anti-CA19.9 antibodies that could potentially be used for the treatment of breast, lung, stomach, colorectal, pancreas and prostate cancer.

"We believe that these newly acquired immunotherapeutic antibody products have the opportunity to become significantly more effective when combined with chemotherapy, radioimmuno therapy or photodynamic therapy," said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest. "As one of the original inventors of this technology, I have a deep understanding of the potential of these compounds to become more efficacious treatments for cancer when used as an adjunct in combination with these established therapies. We intend to expeditiously evaluate the potential of the acquired products for conducting a registration trial for one or more combination therapies, which, if successful, could lead directly to one or more applications for regulatory approval."

As part of the transaction, Paladin receives an upfront payment of $37,500 and 1.5 million common shares of Quest, with an additional 1.5 million common shares to be issued to Paladin on or before December 31, 2010. Paladin may also receive an additional 2
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... certain matters, including the appointment of auditors, its annual ... 2015 (the "Meeting") was adjourned, as previously disclosed on ... a.m. ( Toronto time). The date ... previous disclosed. The Meeting will reconvene at the offices ...
(Date:3/26/2015)... 2015 PAREXEL International Corporation (Nasdaq: ... research organization , announced today that the ... acquire all of the business assets of privately-owned ... of specialized pharmacovigilance services, based in Chandigarh, ... assessment, monitoring, and prevention of adverse effects ...
(Date:3/25/2015)... Russia,s pharmaceutical market is one of the ... to its absolute size, plus a growing economy and ... from Business Monitor International. The Russian market is set ... pharmaceutical market, with growth estimates around 10-15% annually reaching ... About Green Cross Green Cross ...
(Date:3/25/2015)... March 25, 2015  S&P Capital IQ (MHFI) ... Stock Report coverage on Abattis Bioceuticals Corp . ... ATT): is a specialty biotechnology company with capabilities ... and marketing proprietary ingredients, bio-similar compounds, patented equipment ... North America . The company seeks ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... - Asian populations with regard to risk associated in the ... osteoporosis or cardiovascular disease, ... in response to nutritional ... WALTHAM, Mass., Feb. 28 Interleukin Genetics,Inc. (Amex: ILI ...
... Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, What: ... Conference Call, When: ... http://www.transgenomic.com/events.asp?id=6 , How: ... address above., ...
... ANDS ) today announced that patient dosing has ... oral TLR7 agonist prodrug, in,patients with advanced solid tumors. ... to identify pharmacologically active doses,and preliminary antitumor activity as ... II trials., The Phase I trial is a ...
Cached Biology Technology:Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 2Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 3Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 4Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... (March 30, 2011)The Society of Interventional Radiology Foundation,s Discovery ... invasive medicine into new areas of discovery, announced a ... provider of medical devices for vascular access and the ... in Marlborough, Mass., has pledged $500,000 and was named ...
... German . , Innovations relating to mobility, energy, ... at the 2011 Hannover Messe from April 4 8. ... a hybrid Porsche racing car, developments in battery research, materials ... European energy supply system, and the Energy Solution Center (EnSoC) ...
... blood be the key to creating cyborg interfaces? Circuitry that ... device, such as a robotic limb or artificial eye might ... components. Writing in the International Journal of Medical ... a "memristor" can be made using human blood. Memristors were ...
Cached Biology News:Fueling interventional radiology growth: SIR Foundation announces Navilyst Medical Pledge 2KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5Blood simple circuitry for cyborgs 2
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... 2000 One-Step FP Standardization Kit is ... low fluorescence polarization values of fluorescein ... Beacon 2000 System. It also allows ... generated by their instrument to the ...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Biology Products: